ZYBRESTAT ONCOLOGY Publications, presentations, and Posters

Review Articles

 Dietmar W Siemann † , David J Chaplin & Patricia A Walicke
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Expert Opin. Investig. Drugs (2009) 18(2)

P Hinnen and FALM Eskens
Vascular disrupting agents in clinical development
British Journal of Cancer (2007), 

 ZYBRESTAT in ATC

 Colin J. Mooney, Govardhanan Nagaiah, Pingfu Fu, Jay K. Wasman, Matthew M. Cooney, Panos S. Savvides, Joseph A. Bokar, Afshin Dowlati, Ding Wang,5 Sanjiv S. Agarwala, Susan M. Flick, Paul H. Hartman, Jose D. Ortiz, Pierre N. Lavertu, and Scot C. Remick
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome Thyroid: Volume 19, Number 3, 2009

zybrestat in Platinum-Resistant Ovarian Cancer Phase 2 Study 

G. Rustin et al.
ZYBRESTAT™ (IV) Phase II in Platinum-Resistant Ovarian Cancer
International Gynecological Cancer Society Meeting – October 2008

Other Phase 2 Study zybrestat oncology  

Garon, E., Kabinavar, F., Balkissoon, J., Lu, SP., Neidhart, J., Gabrial, N., Oliveria, M.

Interim Safety Results of a Randomized Ph 2 Trial of a Tumor Vascular Disrupting Agent Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung cancer (NSCLC) AACR, November 2009

Rustin, G., Nathan, P., Boxall, J., Saunder, L., Gaya, A., Ganeson, T., Wang, D.
A dose escalation study combining combretastatin A4 phosphate (CA4P) with carboplatin or paclitaxel in patients with advanced cancer
EORTC, November, 2005

W. Akerley, E. Horvath, M. Yu, M. Schabel, G. Morel, K. Jackson
Randomized, Phase I-II Trial of 2 Doses of Combretastatin with Paclitaxel/Carboplatin for Imagable Malignancies
American Society of Clinical Oncology (ASCO) – June 2007

Phase 1 zybrestat oncology 

P. Nathan et al.
ZYBRESTAT™ + Bevacizumab Phase Ib Results
American Society of Clinical Oncology (ASCO) - June 2008

Quan-Sing Ng, Vicky Goh, Dawn Carnell, Khalda Meer, Anwar R. Padhani, Michele I. Saunders, And Peter J. Hoskin
Tumor Antivascular Effects Of Radiotherapy Combined With Combretastatin A4 Phosphate In Human Non–small-Cell Lung Cancer
Int. J. Radiation Oncology Biol. Phys., Vol. 67, No. 5, pp. 1375–1380, 2007

Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ.
Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin.
Clinical Cancer Research 11:1527-33 February 15, 2005

Matthew M. Cooney, Tomas Radivoyevitch, Afshin Dowlati, Beth Overmoyer, Nathan Levitan, Kelly Robertson, Sandra L. Levine, Kathleen DeCaro, Carol Buchter, Anne Taylor, Bruce S. Stambler and Scot C. Remick
Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer
Clinical Cancer Research, Vol. 10, 96–100, January 1, 2004

Anderson H., Yap J., Miller M., Robbins A., Jones T., Price P.
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate Journal of Clinical Oncology, Vol 21, No 15 (August 1), 2003: pp 2823-2830

Gordon J.S. Rustin, Susan M. Galbraith, Helen Anderson, Michael Stratford, Lisa K. Folkes, Luiza Sena, Lindsey Gumbrell, and Patricia M. Price
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate
Journal of Clinical Oncology, Vol 21, No 15 (August 1), 2003: pp 2815-2822

James P. Stevenson, Mark Rosen, Weijing Sun, Maryann Gallagher, Daniel G. Haller, David Vaughn, Bruce Giantonio, Ross Zimmer, William P. Petros, Michael Stratford, David Chaplin, Scott L. Young, Mitchell Schnall, and Peter J. O'Dwyer
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
Journal of Clinical Oncology, Vol 21, No 23 (December 1), 2003: pp 4428-4438

Dowlatti A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC.
A Phase I Pharmacokinetic and Translational Study of the novel Vascular Targeting Agent CA4P on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer.
Cancer Research 62(12):3408-16 June 15, 2002

Preclinical zybrestat Oncology 

Dietmar W. Siemann And Wenyin Shi
Dual Targeting of Thmor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or OXi4503)
AntiCancer Research, Volume 28, April 21, 2008

Fang Zhang, Cheng Sun, JingxiaWu, Chunyan He, Xinjian Ge, Wenming Huang, Yong Zou, Xingmiao Chen, Wei Qi, Qiwei Zhai
Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice
Pharmacological Research. March 11, 2008

Isabelle Petit, Matthias A Karajannis, Loic Vincent, Lauren Young, Jason Butler, Andrea T Hooper, Koji Shido, Hermann Steller, David J Chaplin, Eric Feldman and Shahin Rafii
The microtubule targeting agent, CA4P, regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death
Blood: Prepublished online Nov 16, 2007

Sai-Ching J. Yeung*, Miaorong She, Huiling Yang, Jingxuan Pan, Lily Sun, David Chaplin
Combination Chemotherapy including Combretastatin A4 Phosphate and Paclitaxel is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model
J Clin Endocrin Metab. First published ahead of print June 5, 2007

Beth A. Salmon, Howard W. Salmon, Dietmar W. Siemann,
Monitoring the treatment efficacy of the vascular disrupting agent CA4P
European Journal of Cancer, Volume 43, April 2007

Yuval Shaked, Alessia Ciarrocchi, Marcela Franco, Christina R. Lee, Shan Man, Alison M. Cheung, Daniel J. Hicklin, David Chaplin, F. Stuart Foster, Robert Benezra, Robert S. Kerbel
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
SCIENCE VOL 313 22 September 2006

Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin D, May C, Rafi S. November 2005.
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
J. Clin. Invest. 115:2992-3006.

Joshua M. Dziba, Regina Marcinek, Gopalakrishnan Yenkataraman, Jill A, Robinson, and Kenneth B. Ain
Combretastatin A4 Phosphate Has Primary Antineoplastic Activity Against Human Anaplastic Thyroid Carcinoma Cell Lines and Xenograft Tumors
THYROID, Volume 12, Number 12, 2002

Arnd S. Boehle, MD, Bence Sipos, MD, Ursula Kliche, Holger Kalthoff, PhD, and Peter Dohrmann, PhD
Combretastatin A-4 Prodrug Inhibits Growth of Human Non-Small Cell Lung Cancer in a Murine Xenotransplant ModelBlood:
2001 by The Society of Thoracic Surgeons

ZYBRESTAT for Ophthalmology Publications, presentations, and Posters

 D. Brown & T. Wong
ZYBRESTAT™ (IV) Phase II in Myopic Macular Degeneration
Association for Research in Vision and Ophthalmology (ARVO) May 2007

ZYBRESTAT for Ophthalmology PreclinicaL

Escalona-Benz E, Jockovich ME, Murray TG, Hayden B, Hernandez E, Feuer W, Windle JJ. January 2005
Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma.
IOVs. 46(1):8-11.

Nambu H, Nambu R, Melia M, Campochiaro P. August 2003.
Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization.
IOVS. 44(8):3650-5

Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R. March 2002
Inhibition of proliferative retinopathy by the anti-vascular agent Combretastatin A-4.
American Journal of Pathology 160(3):1097-1

OXi4503 PUBLICATIONS, PRESENTATIONS, AND POSTERS

OXI4503 Phase I oncology Studies

D. Patterson et al.

OXi4503 Interim Phase I Results
American Society of Clinical Oncology (ASCO) - June 2

OXI4503 PRECLINCIAL oncology Studies

Bronwyn G. Siim, Patricia Walicke, David J. Chaplin.
Activity of the vascular disrupting agent Oxi4503 against an acute myelogenous leukemia xenograft model
To be presented at the AACR Annual Meeting, April 2009

B. Pedley et al.
Effective Therapy Of Colorectal Cancer Liver Metastases Using Ombretastatin A1 Di-Phosphate
National Cancer Research Institute - October 2008

Yuval Shaked, Terence Tang, Jill Mayer, Laura Daenen, Shan Man, Ping Xu, Shi-Rong Cai, John Wong, Jeffrey Arbeit, Judy Varner, Emile E. Voest, David Chaplin, Adrian Harris, Paul Nathan, Gordon Rustin, Francesco Bertolini, Daniel D. Link, Robert S. Kerbel
Molecular mechanisms responsible for vascular disrupting agent-induced acute mobilization and tumor homing of circulating endothelial progenitor cells
AACR Annual Meeting, April 2008

Lisa K. Folkes, Martin Christlieb, Edyta Madej, Michael R. L. Stratford, and Peter Wardman
Oxidative Metabolism of Combretastatin A-1 Produces Quinone Intermediates with the Potential To Bind to Nucleophiles and To Enhance Oxidative Stress via Free Radicals
Chem. Res. Toxicology. June, 2007, 20, 1885–1894

Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert JW, Martin SW, Bibby MC. Nov-Dec 2002
Anti-tumor and anti-vascular effects of the novel tubulin-binding agent Combretastatin A-1 phosphate.
Anticancer Research. 22(6C):3933-40.

Hill SA, Tozer GM, Pettit GR, Chaplin DJ. May-June 2002
Preclinical evaluation of the antitumor activity of the novel vascular targeting agent OXi4503. Anticancer Research 22(3):1453-8

Holwell SE, Cooper PA, Grosios K, Lippert JW, Pettit GR. March-April 2002
Combretastatin A-1 phosphate: A novel tubulin-binding agent with in vivo anti-vascular effects in experimental tumors.
Anticancer Research 22(2A):707-11